VANGUARD GROUP INC 13D and 13G filings for Haemonetics Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:06 pm Purchase | 2023-12-29 | 13G | Haemonetics Corporation HAE | VANGUARD GROUP INC | 5,406,309 10.650% | 163,473 (+3.12%) | Filing |
| 2023-02-09 11:22 am Purchase | 2022-12-30 | 13G | Haemonetics Corporation HAE | VANGUARD GROUP INC | 5,242,836 10.360% | 47,641 (+0.92%) | Filing |
| 2022-10-11 10:07 am Purchase | 2022-09-30 | 13G | Haemonetics Corporation HAE | VANGUARD GROUP INC | 5,195,195 10.120% | 314,259 (+6.44%) | Filing |
| 2022-02-10 08:16 am Purchase | 2021-12-31 | 13G | Haemonetics Corporation HAE | VANGUARD GROUP INC | 4,880,936 9.550% | 28,654 (+0.59%) | Filing |
| 2021-02-10 10:57 am Sale | 2020-12-31 | 13G | Haemonetics Corporation HAE | VANGUARD GROUP INC | 4,852,282 9.560% | -378,913 (-7.24%) | Filing |